PT-141 (bremelanotide) is FDA-approved for low sexual desire in premenopausal women. Learn what PT-141 is used for, dosing, side effects, and research.
PT-141 (bremelanotide) is a prescription medication FDA-approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a subcutaneous injection before anticipated sexual activity and works by activating melanocortin receptors in the brain rather than by altering hormone levels. PT-141 is not approved for men, for postmenopausal women, or as a general sexual enhancer.
What PT-141 Is and How It Works
PT-141 is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), a peptide involved in appetite, pigmentation, and sexual behavior. Bremelanotide binds melanocortin receptors—especially MC4R—in the central nervous system.
That mechanism makes PT-141 different from familiar erectile dysfunction drugs. It does not widen blood vessels or boost testosterone. Instead, it acts on brain pathways tied to desire and arousal.
When people search what is pt 141 peptide used for, they often assume it is a hormone or a vasodilator. It is neither. PT-141 is a melanocortin receptor agonist with a narrow approved indication.
FDA-Approved Use: HSDD in Premenopausal Women
The FDA approved bremelanotide in 2019 under the brand name Vyleesi for acquired, generalized HSDD in premenopausal women. HSDD is defined as persistently low sexual desire that causes marked distress or interpersonal difficulty.
Understanding what is pt 141 good for starts with that specific diagnosis. It is not approved for situational low desire, for relationship problems, or for women who simply want to increase libido.
- Dose: 1.75 mg injected subcutaneously into the abdomen or thigh.
- Timing: At least 45 minutes before anticipated sexual activity.
- Frequency: No more than one dose in 24 hours and no more than eight doses per month.
If a woman sees no improvement after eight weeks of consistent use, the prescribing information recommends discontinuing PT-141.
Vyleesi is the only FDA-approved brand of PT-141. It is not available as a generic, and it is not the same as compounded or research-grade bremelanotide.
Off-Label and Investigational Uses
Researchers have studied PT-141 in men with erectile dysfunction, including some who did not respond to PDE5 inhibitors like sildenafil. Small trials showed modest improvements in erectile function, but the data are not strong enough for approval.
PT-141 is not FDA-approved for erectile dysfunction in men. It is also not approved for postmenopausal women or for treating low desire caused by antidepressants or other medications.
Other peptides have entirely different applications. Someone asking what is igf-1 lr3 used for is typically exploring muscle growth and recovery research, while what is kpv peptide used for relates to inflammation and gut health. PT-141 does not belong to either category.
Dosing, Timing, and Practical Considerations
PT-141 comes as a single-use autoinjector pen. The standard dose is 1.75 mg, and the injection site should be rotated to reduce irritation.
Because nausea is common, some clinicians suggest using PT-141 on an empty stomach. Alcohol may worsen nausea and is generally discouraged around the time of dosing.
The autoinjector is designed for subcutaneous use in the abdomen or thigh. Do not inject into the same spot repeatedly, and follow the manufacturer's instructions for disposal.
PT-141 is sometimes sold as a lyophilized powder in research settings rather than as a prescription pen. That is why people also ask what is bacteriostatic water for injection used for—it is a diluent used to reconstitute powdered peptides, though research-grade PT-141 is not the same as the FDA-approved product.
Side Effects and Safety Considerations
Nausea is the most frequently reported side effect of PT-141, affecting roughly 40% of users in clinical trials. Flushing, headache, vomiting, and injection site reactions are also common.
Bremelanotide can cause a transient rise in blood pressure and a slight drop in heart rate. It is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
The label also warns about focal hyperpigmentation, including darkening of the skin, gums, or existing moles. Anyone with a history of melanoma or suspicious skin lesions should discuss risks with a healthcare professional.
PT-141 is not recommended during pregnancy. Safety and effectiveness in men, in postmenopausal women, and in people under 18 have not been established.
How PT-141 Compares to Other Options
PT-141 is one of several prescription options for sexual dysfunction, and each works differently.
| Feature | PT-141 (bremelanotide) | Flibanserin | Sildenafil | Testosterone |
|---|---|---|---|---|
| FDA-approved use | HSDD in premenopausal women | HSDD in premenopausal women | Erectile dysfunction | Hypogonadism |
| Route | Subcutaneous injection | Oral, daily | Oral | Injection, gel, or patch |
| Timing | As needed, 45 minutes before | Daily at bedtime | 30–60 minutes before | Ongoing therapy |
| Mechanism | Melanocortin receptor agonist | Serotonin receptor modulator | PDE5 inhibitor | Androgen receptor agonist |
| Approved for men? | No | No | Yes | Only for diagnosed hypogonadism |
PT-141 is not a substitute for sildenafil in men, and it is not a hormone replacement therapy. The choice between these options should be made with a clinician who knows the patient's full medical history.
Legal and Regulatory Status in the US
Bremelanotide is available only by prescription in the United States. It is not a controlled substance, but it is not sold legally as a dietary supplement or research chemical for human use.
Online vendors often market PT-141 peptide for injection without a prescription. Those products are not FDA-approved, may be impure, and carry unknown risks.
Because PT-141 requires a prescription, telehealth platforms that prescribe it must follow state and federal rules. Possessing it without a prescription is not legal for personal use.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, but only for hypoactive sexual desire disorder in premenopausal women. It is sold under the brand name Vyleesi and is not approved for men, postmenopausal women, or general libido enhancement.
How long does PT-141 take to work?
PT-141 is injected at least 45 minutes before anticipated sexual activity. Effects typically last about two to three hours, and the medication should not be used more than once per day or more than eight times per month.
Can men use PT-141?
PT-141 is not FDA-approved for men. Some research suggests it may improve erectile function in certain men, but the evidence is limited and the safety profile in men is not well established. A healthcare professional should be consulted before any off-label use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.